Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Ferreri AJ, et al. Among authors: orvieto e. J Clin Oncol. 2003 Jan 15;21(2):266-72. doi: 10.1200/JCO.2003.09.139. J Clin Oncol. 2003. PMID: 12525518 Free article.
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ, Dell'Oro S, Capello D, Ponzoni M, Iuzzolino P, Rossi D, Pasini F, Ambrosetti A, Orvieto E, Ferrarese F, Arrigoni G, Foppoli M, Reni M, Gaidano G. Ferreri AJ, et al. Among authors: orvieto e. Br J Haematol. 2004 Sep;126(5):657-64. doi: 10.1111/j.1365-2141.2004.05109.x. Br J Haematol. 2004. PMID: 15327516 Free article.
Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
Nolè F, Minchella I, Colleoni M, Orvieto E, Munzone E, de Braud F, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrida S, Galimberti V, Goldhirsch A, Veronesi U. Nolè F, et al. Among authors: orvieto e. Ann Oncol. 1999 Aug;10(8):993-6. doi: 10.1023/a:1008389106575. Ann Oncol. 1999. PMID: 10509165 Free article. Clinical Trial.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Guarneri V, Dieci MV, Bisagni G, Frassoldati A, Bianchi GV, De Salvo GL, Orvieto E, Urso L, Pascual T, Paré L, Galván P, Ambroggi M, Giorgi CA, Moretti G, Griguolo G, Vicini R, Prat A, Conte PF. Guarneri V, et al. Among authors: orvieto e. Ann Oncol. 2019 Jun 1;30(6):921-926. doi: 10.1093/annonc/mdz055. Ann Oncol. 2019. PMID: 30778520 Free PMC article. Clinical Trial.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV, Guarneri V, Giarratano T, Mion M, Tortora G, De Rossi C, Gori S, Oliani C, Merlini L, Pasini F, Bonciarelli G, Griguolo G, Orvieto E, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P. Dieci MV, et al. Among authors: orvieto e. Oncologist. 2018 Mar;23(3):297-305. doi: 10.1634/theoncologist.2017-0322. Epub 2017 Nov 13. Oncologist. 2018. PMID: 29133514 Free PMC article.
Prediction of response to primary chemotherapy for operable breast cancer.
Colleoni M, Orvieto E, Nolé F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V, Sacchini V, Veronesi P, Zurrida S, Orecchia R, Goldhirsch A. Colleoni M, et al. Among authors: orvieto e. Eur J Cancer. 1999 Apr;35(4):574-9. doi: 10.1016/s0959-8049(99)00005-2. Eur J Cancer. 1999. PMID: 10492630
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer.
Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V. Dieci MV, et al. Among authors: orvieto e. Ann Oncol. 2019 Mar 1;30(3):418-423. doi: 10.1093/annonc/mdz007. Ann Oncol. 2019. PMID: 30657852 Free PMC article. Clinical Trial.
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
Griguolo G, Dieci MV, Giarratano T, Giorgi CA, Orvieto E, Ghiotto C, Berti F, Della Puppa A, Falci C, Mioranza E, Tasca G, Milite N, Miglietta F, Scienza R, Conte P, Guarneri V. Griguolo G, et al. Among authors: orvieto e. J Neurooncol. 2017 Jan;131(2):369-376. doi: 10.1007/s11060-016-2309-4. Epub 2016 Nov 16. J Neurooncol. 2017. PMID: 27853958
Invasive lobular breast cancer: subtypes and outcome.
Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G. Iorfida M, et al. Among authors: orvieto e. Breast Cancer Res Treat. 2012 Jun;133(2):713-23. doi: 10.1007/s10549-012-2002-z. Epub 2012 Mar 8. Breast Cancer Res Treat. 2012. PMID: 22399188
68 results